Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy
Open accessThe DOI matches its Crossref record; 221 of the 221 references it cites were found in a registry or an index; 68 of the 168 sources its claims cite were checked for support.
Abstract
Oncogenesis is associated with intestinal dysbiosis, and stool shotgun metagenomic sequencing in individuals with this condition might constitute a non-invasive approach for the early diagnosis of several cancer types. The prognostic relevance of antibiotic intake and gut microbiota composition urged investigators to develop tools for the detection of intestinal dysbiosis to enable patient stratification and microbiota-centred clinical interventions. Moreover, since the advent of immune-checkpoint inhibitors (ICIs) in oncology, the identification of biomarkers for predicting their efficacy before starting treatment has been an unmet medical need. Many previous studies addressing this question, including a meta-analysis described herein, have led to the description of Gut OncoMicrobiome Signatures (GOMS). In this Review, we discuss how patients with cancer across various subtypes share several GOMS with individuals with seemingly unrelated chronic inflammatory disorders who, in turn, tend to have GOMS different from those of healthy individuals. We discuss findings from the aforementioned meta-analysis of GOMS patterns associated with clinical benefit from or resistance to ICIs across different cancer types (in 808 patients), with a focus on metabolic and immunological surrogate markers of intestinal dysbiosis, and propose practical guidelines to incorporate GOMS in decision-making for prospective clinical trials in immuno-oncology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
33 Valid · 0 Not valid · 70 Not checked · 15 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Comedications often prescribed to patients with cancer, such as proton pump inhibitors (PPIs), antibiotics, anti-inflammatory agents, osmotic laxatives and biguanide antidiabetic drugs, strongly affect the taxonomic composition of the intestinal microbial ecosystem23.”
§ Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy > Introduction > Microbiota in ageing and cancer
What the sources say
- Supportedcites [23] Gacesa, R. et al. Environmental factors shaping the gut microbiome in a Dutch population. Nature 604, 732–739 (2022). source
The section “The disease-associated microbiome is a combination of disease and medication signatures” (p. 23) identifies these medication classes as having the largest observed associations with microbial taxa. It also reports that medication use remained independently associated with microbiome features after accounting for disease, supporting the cited point about taxonomic composition. (LLM, conf=0.90)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The signature shared 86% of the genera and species identified in the Gut Microbiome Health Index, another broad study (involving ~2,600 and ~1,700 healthy and unhealthy individuals, respectively)36.”
§ Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy > Introduction > Gut OncoMicrobiome Signatures
What the sources say
- Supportedcites [36] Gupta, V. K. et al. A predictive index for health status using species-level gut microbiome profiling. Nat. Commun. 11, 4635 (2020). source
The citation 36 is attached to the identification of the Gut Microbiome Health Index as 'another broad study (involving ~2,600 and ~1,700 healthy and unhealthy individuals, respectively)', and our copy states exactly that: the Results ('A meta-dataset of integrated human stool metagenomes') and Fig. 1a report 4347 pooled shotgun metagenomes — 2636 healthy and 1711 nonhealthy — from 34 published studies, and the Abstract/Discussion describe GMHI as formulated on 50 microbial species (7 health-prevalent, 43 health-scarce). The same prevalence-based approach was also run at other taxonomic ranks including genus ('Healthy and nonhealthy guts show species-level differences': Genus, 68.2% balanced accuracy, Supplementary Table 2), so taxa at both genera and species level are identified in the source. The 86% overlap figure is the citing paper's own comparison of its DMP signature with GMHI taxa and is not attributed to this source, so nothing here is unsupported. (LLM, conf=0.85)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“chemotherapy was associated with a substantial shift in the alpha and beta diversity of stool composition in women with breast cancer towards an anti-inflammatory pattern27, entailing a relative under-representation of distinct species commonly found across several pathological disorders (Veillonella parvula, Veillonella atypica, Eggerthella lenta and E. asparagiformis)23.”
§ Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy > Introduction > GOMS and prognostic value
What the sources say
- Partly supportedcites [27] Terrisse, S. et al. Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment. Cell Death Differ. 28, 2778–2796 (2021). sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [23] Gacesa, R. et al. Environmental factors shaping the gut microbiome in a Dutch population. Nature 604, 732–739 (2022). sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This signature, identified using both supervised machine learning and a meta-analysis, included the bacterial species Solobacterium moorei, Fusobacterium nucleatum, Parvimonas micra, Peptostreptococcus stomatis, Peptostreptococcus anaerobius and Gemella morbillorum”
§ Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy > Introduction > GOMS and prognostic value
What the sources say
- Partly supportedcites [49] Wirbel, J. et al. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat. Med. 25, 679–689 (2019). sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [50] Thomas, A. M. et al. Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation. Nat. Med. 25, 667–678 (2019). sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [73] Beghini, F. et al. Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3. Elife 10, e65088 (2021). sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a cohort of patients with renal cell carcinoma (RCC) receiving second-line treatment with the anti-PD-1 antibody nivolumab, the prevalence of this species was significantly associated with PFS durations of >12 months (P < 0.01)26.”
§ Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy > Introduction > GOMS and prediction of response to ICIs
What the sources say
- Partly supportedcites [26] Derosa, L. et al. Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients. Eur. Urol. 78, 195–206 (2020). sourceExperimental — accuracy not yet measured
Section 3.2 reports higher prevalence of A. muciniphila in nivolumab responders than nonresponders with RCC, and reports its overrepresentation in responders at p < 0.02. It does not report that the species’ prevalence was significantly associated specifically with PFS >12 months at p < 0.01; the PFS finding there concerns overall microbial richness. Section 3.4 says most patients, rather than all, had received one prior treatment line. (LLM, conf=0.87)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
54 more claims · 10 with their cited sources checked
Create a free account to see all 118 claims and to verify the 100 references still open.
- It may state two separate claims as one. 56
- Probably not a substantial claim. 6
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“By contrast, frailty and multimorbidity are correlated with blooms of Enterocloster, Eggerthella, and other opportunists,43 which can be associated with a dysbiotic gut.”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [43]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Three of these species have recently been associated with response in two new studies utilizing MetaPhlAn4, one meta-analysis21 and one phase 1 FMT trial of ICB-naive patients22.”
From Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma (2024) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other bacteria like Enterococcus hirae (Viaud et al., 2013), Bacteroides fragilis (Vétizou et al., 2015), and Eubacterium sp. AM28-29 (Thomas et al., 2023) have been linked to improved responses in preclinical and clinical settings, often through mechanisms such as dendritic cell maturation and cytokine production (including IL-12).”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Thomas et al., 2023
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, ∼50% of cancer patients inherently exhibit a highly altered gut microbial composition due to aging, systemic changes caused by cancer, or comorbidities and comedications (Thomas et al., 2023; Yonekura et al., 2022).”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Thomas et al., 2023
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Likewise, an accumulation of immunosuppressive secondary bile acids (e.g., lithocholic or deoxycholic acid) or shifts in trimethylamine N-oxide can signal a microbiome tipping into an unbalanced state—often accompanied by compromised inflammatory control and tumor responsiveness (Silva et al., 2025; Thomas et al., 2023; Varanasi et al., 2025).”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Thomas et al., 2023
Experimental — accuracy not yet measured
14 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy > Introduction > GOMS and immunity
“favourable prognosis in patients with hepatitis C virus-induced hepatocarcinoma in China127”
§ Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy > References
“127. Rong Y Reactivity toward Bifidobacterium longum and Enterococcus hirae demonstrate robust CD8+ T cell response and better prognosis in HBV-related hepatocellular carcinoma.”
Citations
Cites
1 retracted
RETRACTED ARTICLE: Microbiome analyses of blood and tissues suggest cancer diagnostic approach
Poore, G. D., Kopylova, E., Zhu, Q., Carpenter, C., Fraraccio, S., Wandro, S., Kosciolek, T., Janssen, S., Metcalf, J., Song, S. J., et al. (2020) · Nature · doi:10.1038/s41586-020-2095-1 · Cited by 989
RetractedStructure, function and diversity of the healthy human microbiome
The Human Microbiome Project Consortium (2012) · Nature · doi:10.1038/nature11234 · Cited by 11,726
Self-citationHallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887
From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites
Koh, A., De Vadder, F., Kovatcheva-Datchary, P., & Bäckhed, F. (2016) · Cell · doi:10.1016/j.cell.2016.05.041 · Cited by 7,070
Changes of Intestinal Functions in Liver Cirrhosis
Fukui, H., & Wiest, R. (2016) · Inflammatory Intestinal Diseases · doi:10.1159/000444436 · Cited by 6,808
A metagenome-wide association study of gut microbiota in type 2 diabetes
Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., Liang, S., Zhang, W., Guan, Y., Shen, D., et al. (2012) · Nature · doi:10.1038/nature11450 · Cited by 6,762
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Self-citationThe Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic T reg Cell Homeostasis
Smith, P. M., Howitt, M. R., Panikov, N., Michaud, M., Gallini, C. A., Bohlooly-Y, M., Glickman, J. N., & Garrett, W. S. (2013) · Science · doi:10.1126/science.1241165 · Cited by 5,413
Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation
Arpaia, N., Campbell, C., Fan, X., Dikiy, S., van der Veeken, J., deRoos, P., Liu, H., Cross, J. R., Pfeffer, K., Coffer, P. J., et al. (2013) · Nature · doi:10.1038/nature12726 · Cited by 4,838
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Self-citation
Cited by
Precision treatment in advanced hepatocellular carcinoma
Yang, X., Yang, C., Zhang, S., Geng, H., Zhu, A. X., Bernards, R., Qin, W., Fan, J., Wang, C., & Gao, Q. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.01.007 · Cited by 429
Montégut, L., López-Otín, C., & Kroemer, G. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02020-z · Cited by 190
“Importantly, multiple non-malignant age-associated diseases are coupled with similar shifts in the gut micro-flora as are cancers located outside of the gastrointestinal tract [47].”
BackgroundSelf-citationDerosa, L., Iebba, V., Silva, C. A. C., Piccinno, G., Wu, G., Lordello, L., Routy, B., Zhao, N., Thelemaque, C., Birebent, R., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.029 · Cited by 198
Self-citationA gut microbial signature for combination immune checkpoint blockade across cancer types
Gunjur, A., Shao, Y., Rozday, T., Klein, O., Mu, A., Haak, B. W., Markman, B., Kee, D., Carlino, M. S., Underhill, C., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02823-z · Cited by 165
“Unfortunately, previous meta-analyses across metagenomic studies have found limited reproducibility of these candidate microbial biomarkers for ICB response 17–20 .”
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
Björk, J. R., Bolte, L. A., Maltez Thomas, A., Lee, K. A., Rossi, N., Wind, T. T., Smit, L. M., Armanini, F., Asnicar, F., Blanco-Miguez, A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02803-3 · Cited by 156
“For example, Thomas et al. 21 found that Eubacterium sp. AM28 29 (SGB6796 group) was associated with response in nine melanoma cohorts, four of which were not included in our study 5,9,11,36 .”
Self-citation
Metadata
- Authors
- Thomas, A. M., Fidelle, M., Routy, B., Kroemer, G., Wargo, J. A., Segata, N., & Zitvogel, L.
- Affiliations
- University of Trento (IT)
- Inserm (FR)
- Centre Hospitalier de l’Université de Montréal (CA)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Zitvogel, Laurence
- ORCID
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2023-06-26
- Volume
- 20
- Issue
- 9
- Pages
- 583-603
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- PMC
- PMC11258874
- OpenAlex
- W4382020994
- Cited by
- 141
- References
- 220
- Citations by year
- 2026: 33 · 2025: 50 · 2024: 46 · 2023: 12
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Reviews Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Iris (University of Trento) (submittedVersion, other-oa)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- American Association for Cancer Research (SU2C-AACR-IRG-19-17)
- Bristol-Myers Squibb
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Melanoma Research Alliance (4022024)
- Gilead Sciences
- Exelixis
- Seerave Foundation
- European Commission (716575, 964590, 101095604, 825410, 101045015, HORIZON2020, 818368, H2020)
- Agence Nationale de la Recherche (ANR-19-CE15-0029, ANR-21-RHUS-0017)
- Institut National de la Santé et de la Recherche Médicale
- Fondation pour la Recherche Médicale
- Fondation ARC pour la Recherche sur le Cancer
- Ligue Contre le Cancer
- Institut Universitaire de France
- Institut National Du Cancer
- PharmaMar
- National Institutes of Health (1u01ca230551-01a1, H2020, 1U01CA230551)
- Genentech
- University of Texas MD Anderson Cancer Center
- Stand Up To Cancer (SU2C-AACR-IRG-19-17)
- Horizon 2020 Framework Programme (OncoBiome 825410, 818368, 964590, 825410)
- HORIZON EUROPE Framework Programme (818368)
- Canadian Institutes of Health Research
- Fonds de Recherche du Québec - Santé
- Labex Immuno-Oncology
- National Cancer Institute (R01CA219896, 1U01CA230551, U01 CA230551, R01CA230551)
- Daiichi Sankyo Europe
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- gut microbiota, gut dysbiosis, cancer immunotherapy, immune checkpoint inhibitors, predictive biomarkers, immune checkpoint inhibitor response, immune checkpoint inhibitor resistance, chronic inflammatory diseases, stool metagenomics, patient stratification
- MeSH terms
- Humans, Immunotherapy, Neoplasms, Prospective Studies, Biomarkers, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy. https://app.cochat.ai/papers/10.1038/s41571-023-00785-8
- The paper
- Thomas, A. M., Fidelle, M., Routy, B., Kroemer, G., Wargo, J. A., Segata, N., & Zitvogel, L. (2023). Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-023-00785-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.